Aztreonam Inhalation Solution (AZLI) Safety Study in Children with CF and Chronic Pseudomonas Aeruginosa
Study Type:
Interventional
Intervention Category:
Anti-Infective
Study Sponsor:
Gilead
Study Phase:
4
Recruitment Status:
Trial Completed
Study Drug(s):
Cayston
Number of Participants Being Recruited:
60
Single / Multi-Center:
Multi-Center
STUDY BACKGROUND INFORMATION:
This is an open-label, multicenter study in children < 13 years of age with Cystic Fibrosis (CF) and chronic Pseudomonas Aeruginosa (PA) infection in the lower airways to look at the safety of treatment with Aztreonam Inhalation Solution (AZLI) given three times daily for three 28 day on/ 28 day off cycles. The total study duration will be approximately 7 months.
ELIGIBILITY
Age:
1 Days - 12 Years
FEV1:
Not Applicable
P. aeruginosa status:
Positive
B. cepacia status:
Negative
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
Ann and Robert H. Lurie Children's Hospital of Chicago (Pediatric), Chicago, IL, 60611
Contact Information:
Singh, Noopur Phone: (312) 227-6861 Email: nosingh@luriechildrens.org
Intermountain Cystic Fibrosis Center (Pediatric), Salt Lake City, UT, 84132
Contact Information:
Vroom, Jane Phone: (801) 587-7458 Email: jane.vroom@hsc.utah.edu
